Intravenous immune globulin in multiple sclerosis: Clinical and neuroradiological results and implications for possible mechanisms of action

Clinical and Experimental Immunology, Supplement

Volumn 104, Issue SUPPL. 1, 1996, Pages 67-70

  Achiron, A ^a   Barak, Y ^a   Goren, M ^a   Gabbay, U ^a   Miron, S ^a   Rotstein, Z ^a   Noy, S ^a   Sarova Pinhas, I ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

Brain; Intravenous immune globulin; MRI; Multiple sclerosis

Indexed keywords

IMMUNOGLOBULIN;

ADULT; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DOUBLE BLIND PROCEDURE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

ADULT; BRAIN; DOUBLE-BLIND METHOD; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MULTIPLE SCLEROSIS; RECURRENCE;

EID: 0029936727     PISSN: 09642536     EISSN: None     Source Type: Journal    
DOI: 10.1111/cei.1996.104.s1.67     Document Type: Article

References (37)

1. Matthews WB. McAlpine's Multiple Sclerosis, 2nd ed. Edinburgh: Churchill Livingstone, 1991.
2. Antel JP, Freedman MS, Brodovsky S et al. Activated suppressor cell function in severely disabled patients with multiple sclerosis. Ann Neurol 1989; 25:204-7.
3. Adachi K, Kumamoto T, Araki S. Interleukin-2 receptor levels indicating relapse in multiple sclerosis. Lancet 1989; i:559-60.
4. Trottler JL, Clifford DB, McHinis JE et al. Correlation of immunological studies and disease progression in chronic progressive multiple sclerosis. Ann Neurol 1989; 25:172-8.
5. Alvord EC, Kies MW, Suckling AJ. Experimental allergic encephalomyelitis: a useful model for multiple sclerosis. Prog Clin Biol Res 1984; 146:1-554.
6. Carter JL, Hafler DA, Dawson DM et al. Immunosuppression with high-dose IV cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients. Neurology 1988; 38 (Suppl. 2):9-14.
7. British and Dutch multiple sclerosis azathioprine trial group. Double masked trial of azathioprine in multiple sclerosis. Lancet 1988; ii:180-3.
8. Cook SD, Devereux C, Tvoiano R et al. Effect of total lymphocyte irradiation in chronic progressive multiple sclerosis. Lancet 1986; i:1405-9.
9. Dommasch D. Comparative clinical trial of cyclosporine in multiple sclerosis: the pros. Neurology 1988; 38 (Suppl 2):28-9.
10. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis.I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43:655-61.
11. Berkman SA, Lee ML, Gale RP. Clinical uses of intravenous immunoglobulins. Sem Hematol 1988; 25:140-58.
12. Arsura EL, Bick A, Brunner NG, Grob B. Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis. Am J Med Sci 1988; 295:438-43.
13. Van Der Meché FGA, Schmitz PIM, Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 326:1123-9.
14. Van Doorn PA, Brand A, Strengers PFW et al. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, cross-over study. Neurology 1990; 40:209-12.
15. Cherin P, Herson S. Indications for intravenous gammaglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psychiatry 1994; 57 (Suppl.):50-4.
16. Dalakas MC, Illa I, Dambrosia JM et al. A controlled trial of high-dose intravenous imune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329:1993-2000.
17. Achiron A, Pras E, Gilad R et al. Open controlled therapeutic trial of high-dose intravenous immunoglobulins in relapsing-remitting multiple sclerosis. Arch Neurol 1992; 49:1233-6.
18. Achiron A, Gilad R, Margalit R et al. Intravenous gammaglobulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis: delineation of usage and mode of action. J Neurol Neurosurg Psychiatry 1994; 57(Suppl.):57-61.
19. Cook SD, Troiano R, Rohowsky-Kochin C et al. Intravenous gammaglobulin in progressive MS. Acta Neurol 1992; 86:171-5.
20. Van Engelen BG, Hommes OR, Pinckers A et al. Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. Ann Neuro 1992; 32:834-5.
21. Noseworthy JH, Rodriguez M, An KN et al. IVIG treatment in multiple sclerosis: pilot study results and design of placebo-controlled, double-blind clinical trial. Ann Neurol 1994; 36:325(Abstract).
22. Sandor M, Houlden BW, Bluestone JA et al. In vitro and in vivo activation of murine γ/δ T cells induce the expression of IgA, IgM, and IgG Fc receptors. J Immunol 1992; 148:2363-9.
23. Sandor M, Daeron M, Ibraghimov A, Lynch RG. Fc receptor expression on murine epidermal T cells. FASEB J 1991; 5:6339(Abstract).
24. Antel JP, Owens T. The attraction of adhesion molecules. Ann Neurol 1993; 34:123-4.
25. Raine CS, Cannella B. Adhesion molecules and central nervous system inflammation. Semin Neurosci 1992; 4:201-11.
26. Nyland H, Nilsen R. Localization of Fcγ receptors in the human central nervous system. Acta Path Microbiol Immunol Scand 1982; 90:217-21.
27. Ulvetad E, Williams K, Vedeler C et al. Reactive microglia in multiple sclerosis lesions have an increased expression of receptors for the Fc part of IgG. J Neurol Sci 1994; 121:125-31.
28. Ulvetad E, Williams K, Matre R et al. Fc receptors for IgG on cultured human microglia mediate cytotoxicity and phagocytosis of antibody coated targets. J Neuropathol Exp Neurol 1994; 53:27-36.
29. Sharief MK, Hentfes R. Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. New Engl J Med 1991; 325:467-72.
30. Selma KW, Raine CS, Cannella B, Brosnan CF. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 1991; 87:949-54.
31. Selma KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988; 23:339-46.
32. Baker D, Butler D, Scallon BJ et al. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur J Immunol 1994; 24:2040-8.
33. Abe Y, Horiuchi A, Miyake M, Kimura S. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 1994; 139:5-19.
34. Andersson U, Bjork L, Skansén-Saphir U, Andersson J. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 1994; 139:21-42.
35. Achiron A, Margalit R, Hershkoviz R et al. Intravenous immunoglobulin treatment of experimental T-cell mediated autoimmune diseases: up-regulation of T cell proliferation and down-regulation of TNF-α secretion. J Clin Invest 1994; 93:600-5.
36. Rodriguez M, Lennon VA. Immunoglobulins promote remyelination in the central nervous system. Ann Neurol 1990; 27:12-7.
37. Rodriguez M. Immunoglobulins stimulate central nervous system remyelination: electron microscopic and morphometric analysis of proliferating cells. Lab Invest 1991; 64:358-70.